# Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

> **NCT04333576** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 800 (estimated)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Elagolix
- **DRUG:** Placebo
- **DRUG:** Combined Oral Contraceptive

## Key facts

- **NCT ID:** NCT04333576
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-10
- **Primary completion:** 2029-03
- **Final completion:** 2030-06
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04333576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04333576, "Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04333576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*